Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Refractory or Relapsed Leukemias

NCT00258271 is registered in ClinicalTrials.gov with University of Rochester as lead sponsor.

NCT NCT00258271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00258271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Refractory or Relapsed Leukemias
Lead sponsor
University of Rochester
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2005
Completion date
October 31, 2006
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia